Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: weight

FDA Approves 2 Upadacitinib Formulations for Children with pJIA & PsA

Michele B. Kaufman, PharmD, BCGP  |  August 13, 2024

Upadacitinib, as a tablet and oral solution, is now FDA approved to treat children age 2 years and older with active polyarticular juvenile idiopathic arthritis or psoriatic arthritis.

Filed under:Biologics/DMARDsConditionsDrug UpdatesPediatric Conditions Tagged with:FDAFDA approvalpJIApolyarticular juvenile idiopathic arthritis (JIA)PsAPsA Resource CenterPsoriatic ArthritisU.S. Food and Drug Administration (FDA)upadacitinib

What’s New in Large Vessel Vasculitis

Philip Seo, MD, MHS  |  August 7, 2024

The large vessel vasculitides were a major focus of the 21st International Vasculitis Workshop held in Barcelona in April. The biennial conference brings together specialists from multiple disciplines, including rheumatology, nephrology and immunology, to discuss cutting-edge vasculitis research. This article reviews important points regarding the pathogenesis, diagnosis and management of both giant cell arteritis and…

Filed under:ConditionsGuidanceResearch RheumVasculitis Tagged with:diverticulitisgastrointestinal perforationGiant Cell Arteritisgiant cell arteritis (GCA)interleukin-17A inhibitorlarge-vessel vasculitisTakayasu arteritis (TAK)Takayasu’s Arteritistocilizumab

Coagulation Education: Treatment Options for Antiphospholipid Syndrome

Jason Liebowitz, MD, FACR  |  July 31, 2024

Dr. Maria Tektonidou discussed the latest recommendations for the treatment of patients with antiphospholipid syndrome (APS), including obstetric and thrombotic subtypes.

Filed under:ConditionsEULAR/OtherGuidanceMeeting ReportsVasculitis Tagged with:Antiphospholipid syndromeAPScardiovascularEULAR 2024obstetric APSpregnancypregnancy complicationsthrombotic APS

Summary of Notable Provisions in CY 2025 Medicare PFS Proposed Rule

From the College  |  July 19, 2024

The ACR will provide comments on several provisions related to Medicare physician payment and the Quality Payment Program.

Filed under:Legislation & AdvocacyPractice Support Tagged with:Medicare Physician Fee Schedule (MPFS)Medicare ReimbursementQuality Payment Program (QPP)

‘Be Proactive & Stay Active’: Advice to Patients

Linda Childers  |  July 8, 2024

Magdalena “Maggie” Cadet, MD, a rheumatologist in New York City, remembers learning about the relationship between physical activity and bone health at a young age. She was 5 years old when she first began taking ballet, jazz and tap-dancing lessons. At 9, she became a competitive figure skater and practiced both dance and ice skating…

Filed under:ConditionsPatient Perspective Tagged with:DietExercise

How to Effectively Diagnose & Treat Macrophage Activation Syndrome

Vanessa Caceres  |  May 30, 2024

“As a resident, [I] felt pretty terrible when [we had] a very sick child and the teams [couldn’t] agree on what to do,” said Lauren Henderson, MD, MMS, on an episode of ACR on Air. She discussed the importance of collaboration across specialties in the identification and treatment of macrophage activation syndrome (MAS).

Filed under:ConditionsPediatric ConditionsVasculitis Tagged with:hemophagocytic lymphohistiocytosis (HLH)macrophage activation syndromeMASpatient care

Ethics Forum: The Current Landscape of Artificial Intelligence in Medicine

Jeanne Gosselin, MD  |  May 6, 2024

A handful of articles on artificial intelligence (AI) have graced the pages of this publication in the past six years, including one by Bharat Kumar, MD, in November 2022. Dr. Kumar highlighted the exciting potential of AI in rheumatology, including machine learning (ML) algorithms for the prediction of response to methotrexate and a predictive model…

Filed under:EthicsPractice SupportTechnology Tagged with:artificial intelligenceDiagnosisEthics Forum

Clinically Significant Pain Relief with a Non-Opioid Drug

Michele B. Kaufman, PharmD, BCGP  |  April 18, 2024

In a phase 3 trial, treatment with VX-548 led to statistically and clinically significant improvements in pain compared with placebo.

Filed under:AnalgesicsDrug UpdatesPain Syndromes Tagged with:VX-548

Research Review of Plant-Based Diet for Patients with Osteoarthritis or Rheumatoid Arthritis

Ryan Basen  |  April 10, 2024

About 30 years ago, early in his career as a rheumatologist, Dirkjan van Schaardenburg, PhD, says patients with osteoarthritis experienced terrible problems with inflammation. The landscape has improved to the point that “people can live with it now,” he says. But they still need help. For example, osteoarthritis affects 7% of the global population, according…

Filed under:ConditionsOsteoarthritis and Bone DisordersResearch RheumRheumatoid Arthritis Tagged with:DietPlants for HealthPlants for Joints

When to Check Drug Levels & Why

Stephen J. Balevic, MD, PhD, RhMSUS  |  March 7, 2024

Checking blood levels of commonly used disease-modifying anti-rheumatic drugs (DMARDs) has gained widespread attention in the rheumatology community, even resulting in a recent guidance document from EULAR for biologics.1 Although a highly useful tool, drug level measurement in rheumatology is not without challenges; many of our drugs violate the basic principles of pharmacology that we…

Filed under:Biologics/DMARDsConditionsDrug UpdatesRheumatoid ArthritisSystemic Lupus Erythematosus Tagged with:adalimumabadherenceazathioprinedosagedosage adjustmentdrug levelsetanerceptHYDROXYCHLOROQUINEinfliximabmycophenoloateSLE Resource Centertherapeutic drug monitoring

  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 93
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences